Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Find studies

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

The study enrolled 181 participants (mean [SD] age, 69.6 [7.2] years; 114 [63.0%] female): 91 to the intervention arm (depression in later life [DIL] intervention) and 90 to care as usual (CAU). 1 key finding →

Participants: 181 Evidence: high

However, the advisory did not apply to conventional antipsychotic medications; the risk of death with these older agents is not known. 1 key finding →

Design: cohort study Participants: 22,890 Evidence: moderate

Prognostic factors for severity and mortality in patients infected with COVID-19: A systematic review

✓ Peer-reviewed alzhub usefulness score 72 out of 100. PloS one 2020-11-17

Identified prognostic factors can help clinicians and policy makers in tailoring management strategies for patients with COVID-19 infectious disease while researchers can utilise our findings to develop multivariable prognostic models that could eventually facilitate decision-making and improve patient important outcomes. 2 key findings →

Design: systematic review Participants: 207 Evidence: high

Treatment of acutely sick, frail, older patients in a GEMU substantially reduced mortality. 2 key findings →

Design: randomized controlled trial Participants: 127 Evidence: high

The risk of dementia or MCI at follow-up is almost doubled in elderly hip surgery patients with postoperative delirium compared with at-risk patients without delirium. 3 key findings →

Design: cohort study Participants: 112 Evidence: moderate

Mean ADAQ scores were: Dialysis Living Will, 71%; Centre for Bioethics Living Will, 70%; and Medical Directive, 60% (F = 8.27, P < 0.001 (repeat measures analysis of variance); the Dialysis Living Will and Centre for Bioethics Living Will scored significantly higher than the Medical Directive). 2 key findings →

Evidence: high

Early specialist PC exposure reduced the risk of hospital-based acute care in the last 30 days of life for all chronic disease groups except dementia. 2 key findings →

Design: cohort study Participants: 169 Evidence: moderate

Long-term health benefits of physical activity--a systematic review of longitudinal studies

✓ Peer-reviewed alzhub usefulness score 71 out of 100. BMC public health 2013-09-08

This review revealed a paucity of long-term studies on the relationship between physical activity and the incidence of NCD. 3 key findings →

Design: cross-sectional Participants: 288,724 Evidence: moderate

The APOE-ε4 allele has long been associated with increased risks of Alzheimer's disease and mortality, but the effect of the less prevalent APOE-ε2 allele on diseases in the elderly and survival remains elusive. 4 key findings →

Design: cohort study Participants: 38,537 Evidence: moderate

Thirteen significant risk factors were identified: age, male gender, lung diseases, dysphagia, diabetes mellitus, severe dementia, angiotensin I-converting enzyme deletion/deletion genotype, bad oral health, malnutrition, Parkinson's disease, and the use of antipsychotic drugs, proton pump inhibitors, and angiotensin-converting enzyme inhibitors. 3 key findings →

Design: systematic review Participants: 21 Evidence: high

This review highlights the complexities of pain in NH residents and has implications for both clinical practice and future research. 5 key findings →

Design: systematic review Evidence: high

Future studies are needed to evaluate the benefits and harms of using antibiotics for patients during EOL care in diverse patient populations. 3 key findings →

Design: meta-analysis Evidence: high

6-month consequences of COVID-19 in patients discharged from hospital: a cohort study

✓ Peer-reviewed alzhub usefulness score 71 out of 100. Lancet (London, England) 2023-06-12

After multivariable adjustment, patients showed an odds ratio (OR) of 1·61 (95% CI 0·80-3·25) for scale 4 versus scale 3 and 4·60 (1·85-11·48) for scale 5-6 versus scale 3 for diffusion impairment; OR 0·88 (0·66-1·17) for scale 4 versus scale 3 and OR 1·76 (1·05-2·96) for scale 5-6 versus scale 3 for anxiety or depression, and OR 0·87 (0·68-1·11) for scale 4 versus scale 3 and 2·75 (1·61-4·69) for scale 5-6 versus scale 3 for fatigue or muscle weakness. 2 key findings →

Design: cohort study Participants: 94 Evidence: moderate

Cost-effective strategies to maintain healthy active lifestyle in aging populations are required to address the global burden of age-related diseases. 2 key findings →

Participants: 14,383 Evidence: high

Multimorbidity (hazard ratio [HR] 4·12 [95% CI 3·41-4·98]), frailty (HR 2·38 [95% CI 1·93-2·93]), and disability (HR 1·73 [95% CI 1·34-2·22]) were associated with increased risk of mortality; these associations were not modified by socioeconomic status. 2 key findings →

Design: cohort study Participants: 308 Evidence: moderate

Hormone replacement therapy increases cardiovascular and thromboembolic risk when started many years after the menopause. 5 key findings →

Participants: 2,196 Evidence: high

This analysis of 2-year retrospective cohort studies of individuals diagnosed with COVID-19 showed that the increased incidence of mood and anxiety disorders was transient, with no overall excess of these diagnoses compared with other respiratory infections. 5 key findings →

Design: cohort study Participants: 47 Evidence: moderate

Our findings suggest that clinicians should consider sedative-associated, hypoxic, and septic delirium, which often co-occur, as distinct indicators of acute brain injury and seek to identify all potential risk factors that may impact on long-term cognitive impairment, especially those that are iatrogenic and potentially modifiable such as sedation. 2 key findings →

Design: cohort study Participants: 1,048 Evidence: moderate

Practice Guidelines for the Management of Community-Acquired Pneumonia in Adults

✓ Peer-reviewed alzhub usefulness score 70 out of 100. Clinical Infectious Diseases 2000-08-01

The of establishing the diagnosis of pneumonia and cause is with the antibiotic studies for of community-acquired studies for of community-acquired The diagnosis of is based on a of clinical and laboratory The diagnosis of is and and as well as disease, congestive heart failure, with pneumonia and cases of and are of do not require and are the of antibiotic antimicrobial is usually for and a chest radiography is usually to establish the diagnosis of examination to or is for detecting pneumonia Chest radiography is considered is for the etiologic the and or conditions. 5 key findings →

Design: randomized controlled trial Evidence: high

Overall, uptake was lower among men than among women (odds ratio [OR] 0·91 [95% CI 0·88-0·94]; p<0·0001), and higher among older age groups (1·48 [1·42-1·54] among those aged 65-69 years vs those aged 55-59 years; p<0·0001), groups with less deprivation (1·89 [1·76-2·04] for the most vs the least deprived areas; p<0·0001), individuals of Asian ethnicity (1·14 [1·09-1·20] vs White ethnicity; p<0·0001), and individuals who were former smokers (1·89 [1·83-1·95] vs current smokers; p<0·0001). 2 key findings →

Design: cohort study Participants: 488 Evidence: moderate

Interventions for preventing delirium in hospitalised patients

✓ Peer-reviewed alzhub usefulness score 69 out of 100. The Cochrane database of systematic reviews 2007-04-18

It is associated with increases in mortality, physical morbidity, length of hospital stay, institutionalisation and costs to healthcare providers. 4 key findings →

Participants: 833 Evidence: high

Black decedents were less likely than White decedents to use hospice for 3 or more days (132 of 378 [34.9%] vs 385 of 834 [46.2%]; P Conclusions and relevance Despite the increase in the use of hospice care in recent decades, racial disparities in the use of hospice remain, especially for noncancer deaths. 1 key finding →

Design: cohort study Participants: 1,212 Evidence: moderate

Patients with osteoarthritis had excess all cause mortality compared with the general population (standardised mortality ratio 1.55, 95% confidence interval 1.41 to 1.70). 2 key findings →

Design: cohort study Participants: 1,163 Evidence: moderate

Preoperative predictors for mortality following hip fracture surgery: a systematic review and meta-analysis

✓ Peer-reviewed alzhub usefulness score 69 out of 100. Injury 2011-06-17

Whilst there is no conclusive evidence of the preoperative predictors for mortality following hip fractures, special attention should be paid to the above 12 strong evidence predictors. 3 key findings →

Design: systematic review Participants: 64,316 Evidence: high

From across this tag

10 of the 862 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed